GR851981B - - Google Patents

Info

Publication number
GR851981B
GR851981B GR851981A GR850101981A GR851981B GR 851981 B GR851981 B GR 851981B GR 851981 A GR851981 A GR 851981A GR 850101981 A GR850101981 A GR 850101981A GR 851981 B GR851981 B GR 851981B
Authority
GR
Greece
Application number
GR851981A
Other languages
Greek (el)
Inventor
Akira Nohara
Yoshitaka Maki
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15916456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR851981(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of GR851981B publication Critical patent/GR851981B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
GR851981A 1984-08-16 1985-08-13 GR851981B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59171069A JPS6150978A (en) 1984-08-16 1984-08-16 Pyridine derivative and preparation thereof

Publications (1)

Publication Number Publication Date
GR851981B true GR851981B (en) 1985-12-16

Family

ID=15916456

Family Applications (1)

Application Number Title Priority Date Filing Date
GR851981A GR851981B (en) 1984-08-16 1985-08-13

Country Status (23)

Country Link
US (2) US4628098A (en)
EP (1) EP0174726B1 (en)
JP (1) JPS6150978A (en)
KR (1) KR920002128B1 (en)
AU (1) AU570130B2 (en)
BG (1) BG60415B2 (en)
CA (1) CA1255314A (en)
DE (3) DE19975017I2 (en)
DK (1) DK171340B1 (en)
ES (1) ES8607288A1 (en)
GE (1) GEP19960313B (en)
GR (1) GR851981B (en)
HK (1) HK4792A (en)
HU (1) HU195210B (en)
IE (1) IE58363B1 (en)
MX (1) MX9203043A (en)
NL (1) NL930109I2 (en)
NO (2) NO163131C (en)
PH (1) PH20946A (en)
SG (1) SG103291G (en)
SU (1) SU1507211A3 (en)
UA (1) UA7140A1 (en)
ZA (1) ZA856117B (en)

Families Citing this family (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3585252D1 (en) 1984-07-06 1992-03-05 Fisons Plc BENZIMIDAZOLES, AND METHOD FOR THE PRODUCTION THEREOF, THE FORMULATION AND USE THEREOF AS ANCIENT ANTI-ACIDIC COMPETITION.
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US6749864B2 (en) 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1276017C (en) * 1986-02-13 1990-11-06 Takeda Chemical Industries, Ltd. Sulfenamide derivatives and their production
DK171989B1 (en) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Process for the preparation of 2- (2-pyridylmethylsulfinyl) benzimidazoles
AU3690289A (en) * 1988-05-25 1989-12-12 Byk Gulden Lomberg Chemische Fabrik Gmbh New fluoralkoxy compounds
JP2536173B2 (en) * 1988-08-18 1996-09-18 武田薬品工業株式会社 Injection
US5223515A (en) * 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
AT391693B (en) * 1988-11-15 1990-11-12 Cl Pharma METHOD FOR PRODUCING 3-5-DIMETHYL-4METHOXYPYRIDINE DERIVATIVES AND NEW INTERMEDIATE PRODUCT THEREFOR
IE64199B1 (en) * 1988-12-22 1995-07-12 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
SE8804628D0 (en) 1988-12-22 1988-12-22 Ab Haessle NEW COMPOUNDS
SE8804629D0 (en) 1988-12-22 1988-12-22 Ab Haessle NEW THERAPEUTICALLY ACTIVE COMPOUNDS
DK0382489T3 (en) * 1989-02-10 1995-01-16 Takeda Chemical Industries Ltd Monoclonal Anti-Human Papillomavirus Antibody, Hybridoma Cell Producing This, and Method of Preparation thereof
US5274099A (en) * 1989-12-20 1993-12-28 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
ATE191213T1 (en) 1990-10-17 2000-04-15 Takeda Chemical Industries Ltd PYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF
TW209174B (en) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
ES2036948B1 (en) * 1991-11-21 1994-09-01 Genesis Para La Investigacion PROCEDURE FOR OBTAINING COMPOUNDS DERIVED FROM PIRIDINE.
WO1994001107A1 (en) * 1992-07-08 1994-01-20 Monsanto Company Benzimidazoles for alleviating stomach ulcers in swine
DK0652751T3 (en) * 1992-07-28 1996-11-18 Astra Ab Injection preparation and injection kit containing omeprazole and its analogues
DK0683776T3 (en) * 1993-02-17 1999-10-18 Byk Gulden Lomberg Chem Fab Substituted heteroarylalkylthiopyridines to control Helicobacter bacteria
ES2060541B1 (en) * 1993-02-26 1995-11-16 Vinas Lab NEW PROCEDURE FOR THE SYNTHESIS OF A DERIVATIVE OF 2- (2-PIRIDILMETILSUFINIL) BENCIMIDAZOLE, AND NEW INTERMEDIATE PRODUCTS OBTAINED WITH THE SAME.
ES2063705B1 (en) * 1993-06-14 1995-07-16 S A L V A T Lab Sa INTERMEDIATE FOR THE SYNTHESIS OF LANSOPRAZOLE AND ITS PROCEDURE FOR OBTAINING.
TW280770B (en) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
US5502195A (en) * 1993-11-04 1996-03-26 Slemon; Clarke Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
CN1048980C (en) * 1994-03-29 2000-02-02 广东汕头鮀滨化学药业总公司 Preparation of pyridine derivative and application thereof
SE9402431D0 (en) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
SE9500422D0 (en) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (en) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
NZ318501A (en) * 1995-09-21 1999-06-29 Pharma Pass Llc Novel composition containing an acid-labile omeprazole and process for its preparation
SE521100C2 (en) * 1995-12-15 2003-09-30 Astra Ab Process for the preparation of a benzimidazole compound
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (en) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6380222B2 (en) 1996-10-11 2002-04-30 Astrazeneca Ab Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
EP0983263A1 (en) * 1997-05-30 2000-03-08 Dr. Reddy's Research Foundation Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
PT1003554E (en) 1997-07-25 2005-03-31 Altana Pharma Ag PUMP INHIBITOR IN THERAPEUTIC COMBINATION WITH ANTIBACTERIAL SUBSTANCES
SE9704870D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
EP1121103B1 (en) 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
AU4387799A (en) * 1998-06-26 2000-01-17 Russinsky Limited Pyridine building blocks as intermediates in the synthesis of pharmaceutically active compounds
SI20019A (en) * 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. An improved process for synthesis of 5-methoxy-2-/(4-methoxy-3,5-dimethyl-2-pyridyl)methyl/ sulphynyl-1h-benzimidazol
WO2000004904A1 (en) * 1998-07-22 2000-02-03 Sepracor Inc. Pharmaceutical compositions comprising hydroxylansoprazole and uses thereof
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
HUP0103464A3 (en) * 1998-08-10 2002-11-28 U S Government Represented By Prodrugs of proton pump inhibitors and pharmaceutical compositions containing them
WO2000009092A1 (en) 1998-08-12 2000-02-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
DE19843413C1 (en) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab New salt form of pantoprazole
JP3926936B2 (en) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 Sulfoxide derivative / acetone complex and production method thereof
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
PT1187601E (en) 1999-06-07 2005-11-30 Altana Pharma Ag NEW FORM OF PREPARATION AND ADMINISTRATION UNDERSTANDING AN INHIBITOR OF THE PUMP INSTABLE INSTABLE IN MEDIUM ACID
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
PT1191025E (en) * 1999-06-30 2005-09-30 Takeda Pharmaceutical LANSOPRAZOL CRYSTALS
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
KR100359256B1 (en) * 1999-10-06 2002-11-04 한미약품공업 주식회사 Improved method of preparing lansoprazole
SE9903831D0 (en) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
SE0000774D0 (en) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
ES2171116B1 (en) * 2000-04-14 2003-08-01 Esteve Quimica Sa PROCEDURE FOR OBTAINING DERIVATIVES OF (((PIRIDIL REPLACED) METAL) UNCLE) BENCIMIDAZOL.
ES2521690T3 (en) * 2000-05-15 2014-11-13 Takeda Pharmaceutical Company Limited Process for producing a (R) -2 - [[[3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridyl] methyl] sulfinyl] -benzimidazole crystal
US7271182B2 (en) 2000-08-04 2007-09-18 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and use thereof
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
PT1337525E (en) 2000-12-01 2011-09-01 Takeda Pharmaceutical Process for the crystallization of (r)- or (s)-lansoprazole
PT1341528E (en) 2000-12-07 2012-03-20 Nycomed Gmbh Rapidly disintegrating tablet comprising an acid-labile active ingredient
JP4241041B2 (en) 2000-12-07 2009-03-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Paste-form pharmaceutical product containing an acid-degradable active ingredient
EP1341523B1 (en) 2000-12-07 2013-01-23 Nycomed GmbH Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
KR100430575B1 (en) * 2001-02-21 2004-05-10 주식회사 씨트리 Method of Preparing Lansoprazole and Its Intermediate
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
SE0101379D0 (en) 2001-04-18 2001-04-18 Diabact Ab Composition that inhibits gastric acid secretion
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (en) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
KR20040025677A (en) * 2001-09-18 2004-03-24 제리아 신야쿠 고교 가부시키 가이샤 Benzimidazole derivatives
EP1437352A4 (en) * 2001-09-25 2004-12-08 Takeda Chemical Industries Ltd Benzimidazole compound, process for producing the same, and use thereof
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CN100562317C (en) 2001-10-17 2009-11-25 武田药品工业株式会社 The granule that contains a large amount of acid labile drugs
SE0104295D0 (en) * 2001-12-18 2001-12-18 Astrazeneca Ab New process
KR20050005437A (en) 2002-04-09 2005-01-13 플라멜 테크놀로지스 Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin
MXPA04009968A (en) 2002-04-09 2004-12-13 Flamel Tech Sa Oral suspension of active principle microcapsules.
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
KR100873419B1 (en) * 2002-06-18 2008-12-11 페어차일드코리아반도체 주식회사 Power Semiconductor device having high breakdown voltage, low on-resistance and small switching loss
BR0312802A (en) * 2002-07-19 2005-04-19 Michael E Garst Proton pump inhibitor prodrugs
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
WO2004012659A2 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
JP2006500380A (en) * 2002-08-21 2006-01-05 テバ ファーマシューティカル インダストリーズ リミティド Purification method of lansoprazole
KR101067795B1 (en) 2002-08-30 2011-09-27 니코메드 게엠베하 The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
SE0203065D0 (en) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
EP2596792A1 (en) * 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
KR20050075424A (en) * 2002-11-18 2005-07-20 테바 파마슈티컬 인더스트리즈 리미티드 Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
EP1743893A1 (en) 2002-11-18 2007-01-17 Teva Pharmaceutical Industries Ltd. Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
DE10254167A1 (en) 2002-11-20 2004-06-09 Icon Genetics Ag Process for the control of cellular processes in plants
KR101169471B1 (en) 2002-12-06 2012-07-30 니코메드 게엠베하 Process for preparing s-pantoprazole
BRPI0310118B1 (en) 2002-12-06 2015-10-20 Altana Pharma Ag A process for preparing optically pure proton pump (ppi) inhibitors having a sulfinyl structure
WO2004056804A2 (en) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004072061A1 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
CA2518780C (en) * 2003-03-12 2014-05-13 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
ES2245277T1 (en) * 2003-03-12 2006-01-01 Teva Pharmaceutical Industries Limited SOLIDOS CRYSTALS AND AMORPHES OF PANTOPRAZOL AND PROCEDURES FOR THEIR PREPARATION.
US7608625B2 (en) * 2003-03-13 2009-10-27 Eisai R & D Management Co., Ltd. Method for treating bruxism and bruxism-related diseases
US20050031696A1 (en) * 2003-04-22 2005-02-10 Dr. Reddy's Laboratories Limited Oral pharmaceutical formulations of acid-labile active ingredients and process for making same
CL2004000983A1 (en) 2003-05-08 2005-03-04 Altana Pharma Ag ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET THAT INCLUDES DIHYDRATED MAGNETIC PANTOPRAZOL, WHERE THE TABLET FORM IS COMPOSED BY A NUCLEUS, A MIDDLE COAT AND AN OUTER LAYER; AND USE OF PHARMACEUTICAL COMPOSITION IN ULCERAS AND
PE20050150A1 (en) 2003-05-08 2005-03-22 Altana Pharma Ag A DOSAGE FORM CONTAINING (S) -PANTOPRAZOLE AS AN ACTIVE INGREDIENT
US7683177B2 (en) * 2003-06-10 2010-03-23 Teva Pharmaceutical Industries Ltd Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
CN1823058A (en) * 2003-07-15 2006-08-23 阿勒根公司 Process for preparing isomerically pure prodrugs of proton pump inhibitors
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005020954A2 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
AU2005216863A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
JP2007523163A (en) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド Methods and compositions for the administration of prodrugs of proton pump inhibitors
WO2005092297A2 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
AR048631A1 (en) * 2004-04-28 2006-05-10 Altana Pharma Ag DERIVATIVES OF DIALCOXY-IMIDAZOPIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES,
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
KR101276915B1 (en) 2004-09-13 2013-06-19 다케다 야쿠힌 고교 가부시키가이샤 Method and apparatus for producing oxidized compound
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
CA2584957C (en) 2004-10-21 2015-08-25 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
EP2417986A1 (en) 2004-11-22 2012-02-15 Anadis Ltd. Bioactive compositions
EP1681056A1 (en) 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
CA2784881C (en) 2005-02-25 2016-02-09 Takeda Pharmaceutical Company Limited Method for producing granules
KR100771659B1 (en) 2005-03-23 2007-10-30 주식회사 카이로제닉스 Method of Preparing Pantoprazole and Its Intermediate
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
JPWO2006132217A1 (en) 2005-06-07 2009-01-08 武田薬品工業株式会社 Crystals of salts of benzimidazole compounds
EP1903039A4 (en) * 2005-06-13 2010-09-22 Takeda Pharmaceutical Injection
US7601737B2 (en) 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
GB0525710D0 (en) * 2005-12-17 2006-01-25 Pliva Hrvatska D O O An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN101389316A (en) 2005-12-28 2009-03-18 武田药品工业株式会社 Controlled release solid preparation
CA2634232C (en) 2005-12-28 2013-08-20 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
US20090143438A1 (en) * 2006-03-10 2009-06-04 Arigen Pharmaceuticals, Inc. Novel Pyridine Derivative Having Anti-Helicobacter Pylori Activity
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
PL2046334T3 (en) 2006-07-25 2015-02-27 Vecta Ltd Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi
WO2008036201A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
WO2008035189A1 (en) * 2006-09-22 2008-03-27 Orchid Chemicals & Pharmaceuticals Limited A method for the purification of lansoprazole
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
RU2491075C2 (en) 2006-12-22 2013-08-27 Айронвуд Фармасьютикалз, Инк. Methods and compositions for treating oesophageal disorders
WO2008081891A1 (en) 2006-12-28 2008-07-10 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
WO2008087665A2 (en) * 2007-01-18 2008-07-24 Matrix Laboratories Ltd Process for preparation of lansoprazole
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
TW200840574A (en) * 2007-04-02 2008-10-16 Univ Nat Taiwan The pharmaceutical component for treating hearing loss disease
EP2181106A1 (en) 2007-07-17 2010-05-05 Ranbaxy Laboratories Limited Process for the preparation op pantoprazole sodium and pantoprazole sodium sesquihydrate
KR20170097787A (en) 2007-10-12 2017-08-28 다케다 파마슈티칼스 유에스에이, 인코포레이티드 Methods of treating gastrointestinal disorders independent of the intake of food
AU2008346115A1 (en) * 2007-12-18 2009-07-16 Watson Pharma Private Limited A process for preparation of stable amorphous R-lansoprazole
EP2292612A3 (en) 2007-12-31 2011-05-04 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
JP2011512416A (en) 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ Composition comprising a combination of omeprazole and lansoprazole and a buffer and method of using the same
US20090227633A1 (en) * 2008-03-04 2009-09-10 Bassam Damaj Methods to inhibit tumor cell growth by using proton pump inhibitors
PT2262790T (en) 2008-03-10 2017-07-18 Takeda Pharmaceuticals Co Crystal of benzimidazole compound
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
NZ589150A (en) 2008-05-14 2012-03-30 Watson Pharma Private Ltd Stable r (+) -lansoprazole amine salt and a process for preparing the same
KR20110079641A (en) 2008-09-09 2011-07-07 아스트라제네카 아베 Method for delivering a pharmaceutical composition to patient in need thereof
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
EP2350044A4 (en) * 2008-10-10 2012-06-06 Celtaxsys Inc Method of inducing negative chemotaxis
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
TW201127375A (en) * 2010-01-08 2011-08-16 Eurand Inc Taste masked topiramate composition and an orally disintegrating tablet comprising the same
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
WO2011138797A2 (en) 2010-05-04 2011-11-10 Cadila Healthcare Limited Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
MY180677A (en) 2010-12-03 2020-12-05 Takeda Pharmaceuticals Co Orally disintegrating tablet
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
AU2011350396A1 (en) 2010-12-27 2013-07-11 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
US9233103B2 (en) 2011-03-25 2016-01-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
MY186477A (en) 2011-11-30 2021-07-22 Takeda Pharmaceuticals Co Dry coated tablet
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN104203938A (en) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers
CA2898362C (en) 2013-01-15 2020-09-01 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
TW201532635A (en) 2013-05-21 2015-09-01 Takeda Pharmaceutical Orally disintegrable tablet
US9457011B2 (en) 2014-02-25 2016-10-04 Muslim D. Shahid Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
CN107365300B (en) * 2017-07-26 2019-08-02 桂林华信制药有限公司 A method of effectively removing impurity in Lansoprazole crude product
CN114163419A (en) * 2021-12-24 2022-03-11 辰欣药业股份有限公司 Preparation method of lansoprazole
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (en) * 1974-05-16 1981-01-26 Haessle Ab PROCEDURE FOR THE PREPARATION OF SUBSTANCES WHICH PREVENT Gastric acid secretion
SE7804231L (en) * 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
ZA825106B (en) * 1981-08-13 1983-04-27 Haessle Ab Novel pharmaceutical compositions
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
SE8300736D0 (en) * 1983-02-11 1983-02-11 Haessle Ab NOVEL PHARMACOLOGICALLY ACTIVE COMPOUNDS
HU195220B (en) * 1983-05-03 1988-04-28 Byk Gulden Lomberg Chem Fqb Process for production of new fluor-alkoxi-benzimidasole-derivatives and medical compositions containig them
US4575554A (en) * 1983-12-05 1986-03-11 The Upjohn Company Substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles as gastric antisecretory agents
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
GB8417171D0 (en) * 1984-07-05 1984-08-08 Beecham Group Plc Compounds
SE8404065D0 (en) * 1984-08-10 1984-08-10 Haessle Ab NOVEL BIOLOGICALLY ACTIVE COMPOUNDS

Also Published As

Publication number Publication date
NL930109I1 (en) 1993-10-18
EP0174726A1 (en) 1986-03-19
CA1255314A (en) 1989-06-06
GEP19960313B (en) 1996-06-24
NL930109I2 (en) 1997-02-03
ES8607288A1 (en) 1986-05-16
NO163131C (en) 1994-10-24
KR920002128B1 (en) 1992-03-12
IE58363B1 (en) 1993-09-08
DK171340B1 (en) 1996-09-16
US4689333A (en) 1987-08-25
US4628098A (en) 1986-12-09
ES546152A0 (en) 1986-05-16
PH20946A (en) 1987-06-10
IE851976L (en) 1986-02-16
DK356485D0 (en) 1985-08-06
SU1507211A3 (en) 1989-09-07
DE3569736D1 (en) 1989-06-01
HU195210B (en) 1988-04-28
DK356485A (en) 1986-02-17
HUT39444A (en) 1986-09-29
JPS6150978A (en) 1986-03-13
JPH0244473B2 (en) 1990-10-04
NO853226L (en) 1986-02-17
HK4792A (en) 1992-01-17
ZA856117B (en) 1986-04-30
AU4589585A (en) 1986-02-20
NO163131B (en) 1990-01-02
SG103291G (en) 1993-02-19
EP0174726B1 (en) 1989-04-26
DE19975020I2 (en) 2009-08-06
BG60415B2 (en) 1995-02-28
DE19975017I2 (en) 2009-08-06
UA7140A1 (en) 1995-06-30
MX9203043A (en) 1992-07-01
NO1995002I1 (en) 1995-03-31
AU570130B2 (en) 1988-03-03
KR870002125A (en) 1987-03-30

Similar Documents

Publication Publication Date Title
GR851981B (en)
GR851351B (en)
DE3419894C2 (en)
AT379850B (en)
GR850498B (en)
GB8518776D0 (en)
DE3401162C2 (en)
AU2219783A (en)
AU2557584A (en)
GR73445B (en)
GR79538B (en)
BG45042A3 (en)
BG45080A1 (en)
BG44829A1 (en)
BG44749A1 (en)
BG44830A1 (en)
BG44848A1 (en)
BG44737A1 (en)
BG44917A1 (en)
BG44933A1 (en)
BG44935A1 (en)
BG45025A1 (en)
BG44723A1 (en)
BG45181A1 (en)
BG44718A1 (en)